33 results about "Immunocompromised patient" patented technology

This invention describes methods of using anti-B cell antibodies, preferably anti-CD20 antibodies, and most preferably Rituximab, to treat B cell lymphomas of the brain, especially primary central nervous system lymphomas (PCNSLs), and to prevent meningeal relapse. The antibodies can be administered intrathecally alone, or in combination with other chemotherapeutics, such as methotrexate, or other anti-B cell antibodies to treat PCNSL in both immunocompromised and non-immunocompromised patients. These antibodies can also be used to diagnose patients with CNS lymphoma, especially in immunocompromised patients.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

The invention provides methods of treating and preventing asthma, laryngitis, symptomatic gastroesophageal reflux disease, pregnancy-induced gastroesophageal reflux disease, noncardiac chest pains, coughing, apnea, dyspepsia, inflammatory bowel disease, irritable bowel syndrome, gastritis, stress ulcers, bleeding peptic ulcers, acute gastrointestinal bleeding, infectious enteritis, collagenous colitis, lymphocytic colitis, chronic diarrhea in immunocompromised patients, esophageal ulcers in immunocompromised patients, idiopathic gastric acid hypersecretion, gastroparesis, gastrointestinal motility disorders, Zollinger-Ellison syndrome, short bowel syndrome, emesis, regurgitation, early satiety, chronic sore throat, abdominal pain, abdominal bloating, nausea, sour stomach, diarrhea, constipation, bacterial infections, refractory ulcers, gastrointestinal disorders induced by NSAIDs, Barrett's esophagus, gastrointestinal disorders caused by steroids, gastrointestinal disorders induced by cholinergic compounds, and fungal or viral-induced ulcers in the gastrointestinal tract by administering a therapeutically effective amount of at least one proton pump to a patient in need thereof. The invention also provides on demand relief of symptoms associated with gastroesophageal reflux disease (GERD), and provides relief from symptoms caused by the consumption of excessive amounts of food and/or alcohol by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof. The invention also provides methods for treating parasitic infections, such as malaria, by administering a therapeutically effective amount of at least one proton pump inhibitor to a patient in need thereof.

Sanitizing Container and Display is an assembly for maintaining and displaying potted plants, cut flowers and flower arrangements in hospitals, home or other environments where immunocompromised patients or those who suffer allergic disease live. This closed plant-holding container is provided with a air filtered ventilation system that establishes adequate air circulation to the plants while filters the chamber out-flow air and clear out any potential harmful microbe, dust, allergen or fumes from chamber out-flow air that would be dangerous for those patients who lacks normal immune protection or are allergic to plant and flower allergens. This enclosed chamber also is provided with an artificial light source for illumination of the plants or flowers. The object of this invention was to create a completely sealed chamber that makes it possible for immunsuppressed patients or those with sever allergic disease to enjoy the loveliness of these natural beauties in their living environment.

IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

This application relates to the production and characterization of a mutant strain of Aspergillus fumigatus. The application also relates to a method for inhibiting siderophore biosynthesis in Aspergillus fumigatus and an assay for identifying drug candidates or other agents having potential inhibitory activity. The method may comprise, for example, the step of inhibiting an enzyme catalyzing siderophore biosynthesis, such as L-ornithine N⁵-oxygenase. In one embodiment the siderophore is a hydroxamate siderophore, such as N′N″N′″-triacetylfusarinine C (TAF) or ferricrocin. A method of preventing or treating fungal infections in a patient is also described comprising administering to the patient an agent suitable for inhibiting fungal secretion of siderophores. The method is particularly useful for immunocompromised patients susceptible to fungal infections caused by Aspergillus fumigatus, such as pulmonary aspergillosis. The invention also relates to diagnostic methods for detecting a biomarker indicative of likely A fumigatus infection in vivo, such as serum presence of TAF.

The invention provides application of arctigenin in preparation of anti-infectious immunity drugs, which belongs to the field of medicine. Arctigenin is a natural monomer extracted from the traditional Chinese medicine burdock; it is discovered that arctigenin can substantially improve the clearance index and the phagocytic index of an immunocompromised patient and enhance non-specific immunity of the patient, exerts good treatment effects on infection caused by parasites, bacteria and viruses and especially has an excellent treatment effect on infectious diseases caused by Gram-positive bacteria. Arctigenin has the advantages of definite therapeutic effects, small toxic and side effects and wide medical application prospects when used for treatment of infectious diseases.

A method for local treatment of severe oral lesions caused by oropharyngeal candidiasis in immunocompromised patients, in particularly having head and neck cancer and undergoing or have undergone radiation therapy, by administering a prolonged release mucoadhesive tablet containing at least one active principle of miconazole. Methods of treating xerostomia in cancer patients having severe oral lesions is also provided.

In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms. The present invention provides, in various aspects, compounds and methods for the treatment of infections, such as biofilm infections or chronic biofilm infections. The chronic biofilm infection may occur in wounds, implanted devices, immunocompromised patients, people with cystic fibrosis, eye infections, etc.

In various aspects, the invention relates to immune tolerant glycosidase therapy. The invention provides methods for treating or preventing infectious disease, including chronic viral infections, and highly contagious infectious agents that present an ongoing challenge for the immune system. The compositions and treatment regimens find use with other antiviral or antimicrobial therapies, as well as in conjunction with vaccination to boost effectiveness and/or extend the duration of protective effect. In certain embodiments, the regimen described herein reduces or eliminates the need for administration of other traditional antiviral or antimicrobial therapies. In various embodiments, the invention finds use in immunocompromised patients to boost immune function.

The invention relates to a method for treating protozoal gastrointestinal disorders in immunocompromised patients. It includes a method for the isolation of a factor from the milk of hyperimmunized animals in a substantially pure form, and to the use of said factor in combination with vitamins and minerals.

The invention provides application of a compound cercosporamide in preparation of an immunoenhancer. The compound has immunoenhancement activity and is used for immunocompromised patients suffering cancers, AIDS, immunodeficiency disorder or aging. The cercosporamide has another name of 4-Dibenzofurancarboxamide. The immunoenhancer comprises an active ingredient cercosporamide and auxiliary materials.